 The primary objective is to assess the safety of two doses of C-Tb 0.01 and 0.1 μg0.1 mL when administered intradermally by the Mantoux technique to patients in the acute phase of treatment against active TB. The secondary objectives are to assess the immune response of two doses 0.01 and 0.1 μg0.1 mL of C-Tb from the size of induration and to assess the safety of unpreserved C-Tb and C-Tb preserved with 0.5 phenol local reactions. 